Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Ig NextGen 16% in PID Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria:~  * Males or females 3 years of age or greater and at least 13 kg at enrolment.~ * PID patients receiving Ig replacement therapy, with a diagnosis of X-linked agammaglobulinemia (XLA) or Common Variable immunodeficiency (CVID) with severe hypogammaglobulinemia.~ * Patients who have received a consistent dose of Intragam®P at 3-, 4-, 5- or 6-weekly intervals, within the range of 0.2 - 0.6 g/kg body weight, for at least six months prior to the Screening visit.~ * Patients must have maintained IgG trough serum level of ≥ 5 g/L during the six months prior to Visit 0, with at least two trough levels to have been documented during this period.~ * Patients and/or their legally acceptable representative/guardian must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements~Exclusion Criteria:~* • Patients newly diagnosed with PID within six months of the Screening visit.~  * Patients with known or suspected severe hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy or other blood products~ * Patients with known selective IgA deficiency or antibodies to IgA~ * Patients receiving immunosuppressive treatment other than topical and/or inhaled steroids and low dose oral steroids.~ * Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Females who are of child bearing potential must have a negative pregnancy test at screening.~ * Patients with protein-losing enteropathies, and kidney diseases with substantial proteinuria~ * Patients with malignancies of lymphoid cells such as chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma.~ * Patients who have within 30 days priors to the study screening visit, participated in a clinical study or used an investigational compound (eg: a new chemical entity not registered for clinical use).~ * Patients with any of the following abnormal lab results:~    * Serum creatinine \>1.5 x Upper limit of Normal (ULN).~   * Serum ALT \& AST \> 2.5 x ULN.~   * Albumin \< 25 g/L~ * Patients who are suffering from an acute or chronic medical condition, other than PID, which may, in the opinion of the Investigator, affect the conduct of the trial.~ * Patients who are not willing or are unable to comply with protocol.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ig NextGen 16% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).